# Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

> **NCT04469179** · PHASE1 · UNKNOWN · sponsor: **SAb Biotherapeutics, Inc.** · enrollment: 21 (actual)

## Conditions studied

- COVID-19
- SARS-CoV2

## Interventions

- **BIOLOGICAL:** SAB-185
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT04469179
- **Lead sponsor:** SAb Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-20
- **Primary completion:** 2021-02-25
- **Final completion:** 2021-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04469179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04469179, "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04469179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*